ClinVar Miner

Submissions for variant NM_007294.4(BRCA1):c.5089T>C (p.Cys1697Arg)

dbSNP: rs80356993
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 14
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel, ClinGen RCV000077594 SCV004101427 pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 2024-04-23 reviewed by expert panel curation The c.5089T>C variant in BRCA1 is a missense variant predicted to cause substitution of Cysteine by Arginine at amino acid 1697 (p.Cys1697Arg). This variant is absent from gnomAD v2.1 (exomes only, non-cancer subset, read depth >=25) and gnomAD v3.1 (non-cancer subset, read depth >=25) (PM2_Supporting met). This BRCA1 missense variant is within a key functional domain and the computational predictor BayesDel (noAF) gives a score of 0.40, above the recommended threshold of 0.28 for prediction of impact on BRCA1 function via protein change. SpliceAI predictor score of 0.05 suggests that the variant has no impact on splicing (score threshold <0.10) (PP3 met). Reported by three calibrated studies to exhibit protein function similar to pathogenic control variants (PMIDs: 30209399, 30257991, 30765603) (PS3 met). Cosegregation analysis of family(ies) carrying this variant provided evidence towards pathogenicity, and has a Bayes Score of 5.24, within the thresholds for moderate pathogenic evidence (LR >4.3 & <=18.7) (PP1_Moderate met; internal lab contributor). Multifactorial likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 2735.2 (based on Cosegregation LR=730.6; Pathology LR=2.41; Family History LR=1.56), above the thresholds for Very strong evidence towards pathogenicity (LR>350) (PP4_Very strong met; PMID: 31131967, 31853058). In summary, this variant meets the criteria to be classified as a Pathogenic variant for BRCA1-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (PM2_Supporting, PP3, PS3, PP1_Moderate, PP4_Very strong).
Ambry Genetics RCV000163799 SCV000214380 likely pathogenic Hereditary cancer-predisposing syndrome 2023-05-11 criteria provided, single submitter clinical testing The p.C1697R variant (also known as c.5089T>C), located in coding exon 16 of the BRCA1 gene, results from a T to C substitution at nucleotide position 5089. The cysteine at codon 1697 is replaced by arginine, an amino acid with highly dissimilar properties. This alteration has been identified in several breast/ovarian cancer kindreds and has not been reported in control populations (Bergthorsson JT, J. Med. Genet. 2001 Jun; 38(6):361-8; Malander S, Eur. J. Cancer 2004 Feb; 40(3):422-8; Thomassen M, Acta Oncol 2008; 47(4):772-7; Biunno I et al. Fam Cancer, 2014 Sep;13:437-44; Machackova E et al. Klin Onkol, 2019;32:51-71; Shao D et al. Cancer Sci, 2020 Feb;111:647-657; Dorling et al. N Engl J Med. 2021 02;384:428-439). Structural modeling and functional assays evaluating homology directed DNA repair, proteolytic degradation, protein stability, transcriptional activation, and peptide binding ability have suggested that this alteration results in reduced or loss of wild type function (Vallon-Christersson J, Hum. Mol. Genet. 2001 Feb; 10(4):353-60; Williams RS, J. Biol. Chem. 2003 Dec;278(52):53007-16; Clapperton JA et al. Nat. Struct. Mol. Biol., 2004 Jun;11:512-8; Glover JN, Fam. Cancer 2006; 5(1):89-93; Anantha RW et al. Elife, 2017 04;6; Findlay GM et al. Nature, 2018 10;562:217-222; Fernandes VC et al. J Biol Chem, 2019 04;294:5980-5992; Petitalot A et al. Mol Cancer Res, 2019 01;17:54-69). Multifactorial and computational likelihood models predict this variant to be deleterious (Karchin R, PLoS Comput. Biol. 2007 Feb; 3(2):e26; Iversen ES, Cancer Epidemiol. Biomarkers Prev. 2011 Jun; 20(6):1078-88; Lee JS et al. J Med Genet, 2018 12;55:794-802; Parsons MT et al. Hum Mutat, 2019 09;40:1557-1578). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the majority of available evidence to date, this variant is likely to be pathogenic.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV001284299 SCV001470009 likely pathogenic not provided 2019-12-01 criteria provided, single submitter clinical testing Not found in the total gnomAD dataset, and the data is high quality. Found in at least one patient with expected phenotype for this gene. Predicted to have a damaging effect on the protein. Located in potentially critical domain of the protein. Assessment of experimental evidence suggests this variant results in abnormal protein function.
Invitae RCV001378925 SCV001576625 likely pathogenic Hereditary breast ovarian cancer syndrome 2023-12-10 criteria provided, single submitter clinical testing This sequence change replaces cysteine, which is neutral and slightly polar, with arginine, which is basic and polar, at codon 1697 of the BRCA1 protein (p.Cys1697Arg). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with breast and/or ovarian cancer (PMID: 11157798, 11389159, 18465347, 36537080). This variant is also known as 5208T>C. ClinVar contains an entry for this variant (Variation ID: 55392). Advanced modeling performed at Invitae incorporating data from internal and/or published experimental studies (PMID: 30209399) indicates that this missense variant is expected to disrupt BRCA1 function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects BRCA1 function (PMID: 11157798, 11389159, 14534301, 20516115, 28398198, 30209399, 30257991). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.
GeneDx RCV001284299 SCV002512833 pathogenic not provided 2022-04-29 criteria provided, single submitter clinical testing Observed in individuals with BRCA1-related cancers (Bergthorsson 2001, Vallon-Christersson 2001, Malander 2004, Cruger 2005, Thomassen 2008); Published functional studies demonstrate a damaging effect: impaired transcriptional activity, binding capacity, protein folding and stability, homologous recombination, cell survival, nuclear localization, and protein expression (Vallon-Christersson 2001, Glover 2006, Lee 2010, Anantha 2017, Findlay 2018, Petitalot 2019, Fernandes 2019); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Also known as 5208T>C; This variant is associated with the following publications: (PMID: 15133502, 30209399, 21447777, 17305420, 11389159, 20516115, 30415210, 30765603, 28398198, 16528612, 14534301, 31131967, 30257991, 18465347, 14746861, 31409081, 24729269, 10946236, 28277317, 24845084, 11157798, 20423312, 24772314, 28781887, 16098011, 32341426, 33087888, 31742824, 25348405)
Baylor Genetics RCV000077594 SCV004212730 likely pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 2023-10-06 criteria provided, single submitter clinical testing
Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet RCV000077594 SCV005045934 pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 2024-05-27 criteria provided, single submitter clinical testing PP3; PS3; PP1_Moderate; PM2_Supporting; PP4_Very_strong
Sharing Clinical Reports Project (SCRP) RCV000077594 SCV000109397 uncertain significance Breast-ovarian cancer, familial, susceptibility to, 1 2013-04-19 no assertion criteria provided clinical testing
Breast Cancer Information Core (BIC) (BRCA1) RCV000077594 SCV000145307 uncertain significance Breast-ovarian cancer, familial, susceptibility to, 1 1999-04-12 no assertion criteria provided clinical testing
Brotman Baty Institute, University of Washington RCV000077594 SCV001242097 not provided Breast-ovarian cancer, familial, susceptibility to, 1 no assertion provided in vitro
Department of Pathology and Laboratory Medicine, Sinai Health System RCV001357130 SCV001552490 likely pathogenic Malignant tumor of breast no assertion criteria provided clinical testing The BRCA1 p.Cys1697Arg variant was identified in 9 of 1204 proband chromosomes (frequency 0.007) from Danish and Swedish individuals or families with hereditary breast and/or ovarian cancer, bilateral or multifocal breast cancer, or invasive epithelial ovarian carcinoma, and was not identified in 360 control chromosomes from healthy individuals (Malander_2004_14746861, Thomassen_2008_18465347, Bergthorsson_2001_11389159). It was not identified in the GeneInsight-COGR, COSMIC, MutDB, ARUP Laboratories, or Zhejiang Colon Cancer databases. The variant was identified in dbSNP (ID: rs80356993) as “With Likely pathogenic, Uncertain significance allele”, ClinVar and Clinvitae (1x classified as likely pathogenic by Ambry Genetics; 2x classified as uncertain significance by SCRP and BIC; 1x not classified by Invitae), LOVD 3.0 (10x with multiple functional study citations), UMD-LSDB (predicted to be pathogenic), BIC Database (3 samples recorded with clinical importance classified as unknown) databases. The variant was not identified in the following control databases: the 1000 Genomes Project, the NHLBI GO Exome Sequencing Project, the Exome Aggregation Consortium (August 8th 2016), or the Genome Aggregation Database (Feb 27, 2017). Multiple functional studies have investigated the effect of this variant. Limited proteolysis to determine stability of the protein fold using in vitro transcribed/translated material noted that the C1697R mutant showed a particularly low protein expression level (Lee_2010_20516115). Using yeast and mammalian-based transcription assays this variant displayed loss of transcriptional activity, suggesting that it represents a disease-associated mutation, in agreement with pedigree analysis (Vallon-Christersson_2001_11157798). This study notes that C1697R is a dramatic amino acid substitution, from a non-polar residue capable of forming disulfide linkages to a positively charged residue, located in a critical alpha-helix based on the structure of XRCC1 BRCT, and that this variant was found to segregate with disease in 1 family in the study and 3 other breast cancer patients from another study (Bergthorsson_2001_11389159). In a protease-based assay, substitution of arginine showed increased sensitivity to chymotryptic cleavage at 20°C, suggesting that destabilizing effects, rather than the introduction of a new trypsin cleavage site, are responsible for the protease sensitivity (Williams_2003_14534301). A peptide-binding assay determined that the variant has a severe folding effect (Williams_2004_15133503). In a study which screened DNA using SSCA and PTT, the BRCA1 construct containing Arg1697 was not able to activate transcription in this system, supporting the classification of C1697R as a pathogenic mutation (Bergthorsson_2001_11389159). The p.Cys1697Arg residue is conserved across mammals and other organisms, and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) suggest that the variant may impact the protein; however, this information is not predictive enough to assume pathogenicity. The variant occurs outside of the splicing consensus sequence and 1 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict a greater than 10% difference in splicing; this is not very predictive of pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more pathogenic role for this variant. This variant is classified as likely pathogenic.
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen RCV001284299 SCV001741498 pathogenic not provided no assertion criteria provided clinical testing
Clinical Genetics Laboratory, Department of Pathology, Netherlands Cancer Institute RCV001284299 SCV001905927 likely pathogenic not provided no assertion criteria provided clinical testing
BRCAlab, Lund University RCV000077594 SCV002588821 pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 2022-08-26 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.